{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05206942",
            "orgStudyIdInfo": {
                "id": "IRB-59526"
            },
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy",
            "officialTitle": "Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "serial-ultrasound-of-solid-tumor-lesions-to-detect-early-response-to-cancer-immunotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-03-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-12",
            "studyFirstSubmitQcDate": "2022-01-12",
            "studyFirstPostDateStruct": {
                "date": "2022-01-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "Primary objective is to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by CEUS, can predict initial objective response to therapy, defined by current standard-of-care\n\nSecondary objectives are to evaluate if there is an optimal ultrasound imaging modality (CEUS or conventional power Doppler or LEAD ultrasound) or optimal time point to predict initial objective response and to assess the correlation of tumor perfusion parameters with change in overall tumor burden, change in diameter on a per-lesion basis, and with 12-month progression-free survival (PFS)."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ultrasound",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receiving standard of care immune checkpoint inhibitor are followed with the ultrasound studies at treatment baseline, 3 weeks and 6 weeks.",
                    "interventionNames": [
                        "Diagnostic Test: Doppler ultrasound",
                        "Diagnostic Test: Long Ensemble Angular-coherence Doppler [LEAD] ultrasound",
                        "Diagnostic Test: Contrast-enhanced ultrasound (CEUS)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Doppler ultrasound",
                    "description": "Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner",
                    "armGroupLabels": [
                        "Ultrasound"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Long Ensemble Angular-coherence Doppler [LEAD] ultrasound",
                    "description": "Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner",
                    "armGroupLabels": [
                        "Ultrasound"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Contrast-enhanced ultrasound (CEUS)",
                    "description": "Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline",
                    "armGroupLabels": [
                        "Ultrasound"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Initial objective response per RECIST v1.1",
                    "description": "Initial objective response is defined as having either Complete Response (CR) or Partial Response (PR) per RECIST v1.1",
                    "timeFrame": "16 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Initial relative change in tumor burden",
                    "description": "defined as relative change in the sum of diameters of all measurable tumors, assessed between treatment 'baseline' and first on-treatment response evaluation",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Initial lesion response",
                    "description": "defined as the relative change in tumor diameter of a single lesion between treatment 'baseline' and first on-treatment response evaluation",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "progression-free survival (PFS)",
                    "description": "defined as not having experienced any PD per RECIST v1.1",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years of age or older\n* pathology-confirmed diagnosis of cancer\n* at least one solid tumor lesion greater than 1 cm in diameter (primary tumor and/or at metastatic site), amenable to ultrasound imaging\n* planned to be treated with ICI therapy (single agent or in combination with any other drug)\n* written informed consent.\n\n  * prior use of any ICI is not necessarily excluded, and patients may be included with the approval of the Protocol Director\n\nSubjects may participate in the study more than once at the discretion of the Protocol Director, for example, if they receive different lines of treatment that all qualify for the study.\n\nExclusion Criteria:\n\n* known hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as polyethylene glycol (PEG)\n* any comorbid condition\\*\\* that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Christian R Hoerner",
                    "role": "CONTACT",
                    "phone": "650-721-3206",
                    "email": "hoerner@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Alice C. Fan, MD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Jeremy Dahl, Ph.D",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Aya Kamaya, M.D",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christian Hoerner",
                            "role": "CONTACT",
                            "phone": "650-721-3206",
                            "email": "hoerner@stanford.edu"
                        },
                        {
                            "name": "Alice Fan, M.D",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}